Overview

Safety and Effectiveness of a New Anti-HIV Drug (AG1549) in Combination With Other Anti-HIV Drugs in HIV-Infected Patients

Status:
Suspended
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to see if two different doses of AG1549 plus other anti-HIV drugs are safe and effective in HIV-infected patients who are not taking anti-HIV drugs.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Agouron Pharmaceuticals
Treatments:
Anti-Retroviral Agents
Capravirine
Lamivudine
Lamivudine, zidovudine drug combination
Nelfinavir
Zidovudine
Criteria
Inclusion Criteria

Patients may be eligible if they:

- Are HIV-positive.

- Are at least 18 years old.

- Have a CD4 cell count of more than 50 cells/mm3.

- Have an HIV level of more than 5000 copies/ml.

Exclusion Criteria

Patients will not be eligible if they:

- Have ever taken any of the following anti-HIV drugs: nonnucleoside reverse
transcriptase inhibitors (NNRTIs), AG1549, Viracept, zidovudine, lamivudine, or
Combivir. Other anti-HIV drugs are allowed only if taken for no more than 30 days with
the last dose taken more than 6 months prior to study entry.

- Have taken an experimental drug within 28 days of study entry.